{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:22:54Z","timestamp":1790446974407,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171341"],"award-info":[{"award-number":["82171341"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,11,4]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To delineate the clinical characteristics and outcomes of late-onset myelin oligodendrocyte glycoprotein antibody-associated disease (LO-MOGAD) and compare them with those of early-onset MOGAD (EO-MOGAD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational cohort study included 199 adult patients with MOGAD. We reviewed the patients\u2019 demographic and clinical data and performed comparative analyses between EO-MOGAD and LO-MOGAD (onset age 18\u201350 and \u226550 years, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 199 patients, 42 had LO-MOGAD. Compared with patients with EO-MOGAD, those with LO-MOGAD patients exhibited a significantly higher incidence of optic neuritis both at the initial attack (66.67% vs 43.31%, p=0.007) and throughout all attacks (72.15% vs 52.51%, p=0.001). Over a similar disease duration, patients with LO-MOGAD exhibited significantly fewer relapsing courses (45.16% vs 70.97%), higher Expanded Disability Status Scale (EDSS) and visual functional system scores at the last visit (all p&lt;0.05). Compared with patients with EO-MOGAD, those with LO-MOGAD had a significantly lower risk of relapse (HR 0.512, 95% CI 0.268 to 0.978, p=0.034), but higher risks of reaching EDSS \u22652 (HR 2.893, 95%\u2009CI 1.524 to 5.494, p&lt;0.001) and visual acuity \u22640.6 (HR 3.097, 95%\u2009CI 1.073 to 8.937, p=0.022). Immunosuppressive therapies significantly reduced the annualised relapse rates of patients with LO-MOGAD, although adverse events leading to drug discontinuation and hospitalisation were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with patients with EO-MOGAD, patients with LO-MOGAD exhibited fewer relapsing courses but worse disability outcomes and should be actively treated.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2024-334613","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T18:17:06Z","timestamp":1733509026000},"page":"655-664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Fewer relapses and worse outcomes of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7784-7340","authenticated-orcid":false,"given":"Yuxin","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-373X","authenticated-orcid":false,"given":"Wenjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-6325","authenticated-orcid":false,"given":"Jingzi","family":"ZhangBao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-3930","authenticated-orcid":false,"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2025061300350688000_96.7.655.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.12.004"},{"key":"2025061300350688000_96.7.655.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8"},{"key":"2025061300350688000_96.7.655.3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909"},{"key":"2025061300350688000_96.7.655.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"2025061300350688000_96.7.655.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330901"},{"key":"2025061300350688000_96.7.655.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105405"},{"key":"2025061300350688000_96.7.655.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0778-x"},{"key":"2025061300350688000_96.7.655.8","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025061300350688000_96.7.655.9","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513515085"},{"key":"2025061300350688000_96.7.655.10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1056944"},{"key":"2025061300350688000_96.7.655.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103845"},{"key":"2025061300350688000_96.7.655.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120039"},{"key":"2025061300350688000_96.7.655.13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"2025061300350688000_96.7.655.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102816"},{"key":"2025061300350688000_96.7.655.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09699-2"},{"key":"2025061300350688000_96.7.655.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327206"},{"key":"2025061300350688000_96.7.655.17","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025061300350688000_96.7.655.18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15239"},{"key":"2025061300350688000_96.7.655.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104237"},{"key":"2025061300350688000_96.7.655.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2009.04.002"},{"key":"2025061300350688000_96.7.655.21","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080120052024"},{"key":"2025061300350688000_96.7.655.22","doi-asserted-by":"publisher","DOI":"10.3109\/01658109509044588"},{"key":"2025061300350688000_96.7.655.23","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1984.01040030721028"},{"key":"2025061300350688000_96.7.655.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102142"},{"key":"2025061300350688000_96.7.655.25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112 (Pt 1)","author":"Weinshenker","year":"1989","journal-title":"Brain (Bacau)"},{"key":"2025061300350688000_96.7.655.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7766-8"},{"key":"2025061300350688000_96.7.655.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11737-8"},{"key":"2025061300350688000_96.7.655.28","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001100"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-334613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:35:25Z","timestamp":1749800125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-334613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jnnp-2024-334613"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-334613","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}